ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CD228/MMAE Antibody-drug Conjugate PF-08046031

In Pfizer’s pipeline, CD228V directed antibody-drug conjugate. Its studies are mostly in Melanoma, led by Pfizer.

Furthest: phase 1, since Jan 23, 20251 company-led study, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer10 open or runningphase 1since Jan 23, 2025Jan 23, 2025none ahead
  • Named in Pfizer’s own pipeline as PF-08046031, phase 1, as of Nov 3, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 23, 2025First study: phase 1 study in MelanomaFirst studyNCT06799533 · 11 enrolled · United States, France, Spain and more

TargetBeta

“CD228V directed antibody-drug conjugate”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of a human immunoglobulin G1 (IgG1) antibody targeting the cell surface antigen cluster of differentiation 228 (CD228; melanotransferrin; MFI2; MELTF; p97; MTf) that is conjugated, via a cleavable linker, to the microtubule-disrupting cytotoxic agent mono…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of a human immunoglobulin G1 (IgG1) antibody targeting the cell surface antigen cluster of differentiation 228 (CD228; melanotransferrin; MFI2; MELTF; p97; MTf) that is ”NCIt, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06799533Melanoma · United States, France, Spain and more1TerminatedFeb 23, 202611

How it is read

Names in the registry

  • “PF-08046031”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.